XML 52 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1

Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned and Accounts Receivable (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Sales revenue, net | Incyte Corporation (Incyte)
Concentration Risk [Line Items]
Percentage of significant accounts receivable	53.00%	26.00%	31.00%
Sales revenue, net | McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC
Concentration Risk [Line Items]
Percentage of significant accounts receivable	12.00%
Sales revenue, net | ASD Healthcare and Oncology Supply
Concentration Risk [Line Items]
Percentage of significant accounts receivable	10.00%
Sales revenue, net | Provention Bio, Inc. (Provention)
Concentration Risk [Line Items]
Percentage of significant accounts receivable	10.00%	43.00%
Sales revenue, net | Zai Lab Limited (Zai Lab)
Concentration Risk [Line Items]
Percentage of significant accounts receivable		15.00%	30.00%
Sales revenue, net | I-Mab Biopharma
Concentration Risk [Line Items]
Percentage of significant accounts receivable			16.00%
Accounts receivable | Incyte Corporation (Incyte)
Concentration Risk [Line Items]
Percentage of significant accounts receivable	25.00%
Accounts receivable | McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC
Concentration Risk [Line Items]
Percentage of significant accounts receivable	16.00%
Accounts receivable | Cardinal Health
Concentration Risk [Line Items]
Percentage of significant accounts receivable	18.00%
Accounts receivable | ASD Healthcare and Oncology Supply
Concentration Risk [Line Items]
Percentage of significant accounts receivable	15.00%
Accounts receivable | Provention Bio, Inc. (Provention)
Concentration Risk [Line Items]
Percentage of significant accounts receivable		84.00%
Accounts receivable | Zai Lab
Concentration Risk [Line Items]
Percentage of significant accounts receivable	12.00%

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 310
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481027/954-310-50-2

+ Details

Name:	us-gaap_ConcentrationRiskLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_IncyteCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_McKessonPlasmaBiologicsAndMcKessonSpecialtyCareDistributionLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_ASDHealthcareAndOncologySupplyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_ProventionBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_ZaiLabLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_IMabBiopharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_CardinalHealthIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_MajorCustomersAxis=mgnx_ZaiLabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: